1,989 reports of this reaction
3.5% of all ABIRATERONE ACETATE reports
#3 most reported adverse reaction
PROSTATIC SPECIFIC ANTIGEN INCREASED is the #3 most commonly reported adverse reaction for ABIRATERONE ACETATE, manufactured by Janssen Biotech, Inc.. There are 1,989 FDA adverse event reports linking ABIRATERONE ACETATE to PROSTATIC SPECIFIC ANTIGEN INCREASED. This represents approximately 3.5% of all 56,299 adverse event reports for this drug.
Patients taking ABIRATERONE ACETATE who experience prostatic specific antigen increased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PROSTATIC SPECIFIC ANTIGEN INCREASED is moderately reported among ABIRATERONE ACETATE users, representing a notable but not dominant share of adverse events.
In addition to prostatic specific antigen increased, the following adverse reactions have been reported for ABIRATERONE ACETATE:
The following drugs have also been linked to prostatic specific antigen increased in FDA adverse event reports:
PROSTATIC SPECIFIC ANTIGEN INCREASED has been reported as an adverse event in 1,989 FDA reports for ABIRATERONE ACETATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PROSTATIC SPECIFIC ANTIGEN INCREASED accounts for approximately 3.5% of all adverse event reports for ABIRATERONE ACETATE, making it one of the most commonly reported side effect.
If you experience prostatic specific antigen increased while taking ABIRATERONE ACETATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.